期刊文献+

瑞舒伐他汀在缺血性心肌病治疗中对心室重塑的影响 被引量:6

下载PDF
导出
摘要 目的观察瑞舒伐他汀在缺血性心肌病治疗中对心室重塑的影响。方法将92例患者随机分为治疗组47例和对照组45例,对照组给予常规治疗,治疗组在此基础上加用瑞舒伐他汀。对开始治疗时及治疗后两组的超声心动图(HP500二维超声心动仪)变化、6min步行距离、NYHA心功能分级评估进行了为期2年的观察。结果治疗组超声心动图变化、6min步行距离、NYHA心功能分级均明显优于对照组,两组比较有显著性差异(P<0.05)。结论瑞舒伐他汀在缺血性心肌病治疗中可以更好地改善心室重塑的过程,延缓心力衰竭的发生和发展,为心血管疾病的治疗带来了广阔的应用前景,在临床中值得进一步研究探讨。
作者 张建华
出处 《中国医药指南》 2010年第5期112-113,共2页 Guide of China Medicine
  • 相关文献

参考文献5

  • 1Greenberg B.Treatment of heart failure:state of the art and prospectives[J].Cardiovasc Pharmacol,2001,38(Suppl 2):S59-S63.
  • 2Hasegawa K,Iwaikanai E,Sasayama S. Neurohormonal regulation of myocardial cell spoptosis during the development of heart failure [J]. J Cell Physiol,2001,186( 1): 11 - 18.
  • 3Tsdeshi A, Yoshihito T, Diane P, et al. Augmented expression of cardiotrophin-1 and its receptor component,gp130,in both left and right ventricles after myocardial infarction in the rat[J]. Mol Cell Cardial,2000,32( 10): 1821-1830.
  • 4Wagner AH,Kohler T, Ruckschloss U, et al. Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation[J]. Arterioscler Thromb Vasc Biol,2000,20(1):61-69.
  • 5Frutos T, Sanche de Miguel L,Farre J,et al. Expression of endothelial type nitric oxide synthetase isoform in human neutrophils:modification by tumor necrosis factor alpha and during acute myocardial infarction[J]. JACC,2001,37(3):800-807.

同被引文献31

  • 1Michael S Kostapanos,Moses S Elisaf.JUPITER and satellites:Clinical implications of the JUPITER study and its secondary analyses[J].World Journal of Cardiology,2011,3(7):207-214. 被引量:8
  • 2万荣军,卜殷中,唐江林,吴光风.曲美他嗪治疗老年缺血性心肌病心力衰竭的疗效[J].医学临床研究,2006,23(5):774-775. 被引量:9
  • 3Richardson P,McKenna WJ,Bristow M. Report of the 1995 WHO/ISFC Task Force on the definition and classification of cardiomyopathies[J].{H}CIRCULATION,1996,(05):841-842.
  • 4Kosmicki M. Metabolic drugs in treatment of ischaemic heart disease[J].Doctors Guide,2001.57-64.
  • 5Wolff AA,Rotmensch HH,Stanley WC. Metabolic approaches to the treatment of ischemic heart disease:the clinicians' perspective[J].{H}Heart Failure Reviews,2002,(02):187-203.
  • 6Kantor PF,Lucien A,Kozak R. The antianginal drug trime-tazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase[J].{H}Circulation Research,2000,(05):580-588.
  • 7Feola M,Biggi A,Francini A. Placebo or trimetazidine 99Tcm tetrofosmin myocardial SPECT and low-dose dobutamine echocardiography in hibernating myocardium[J].{H}ARCHIVES OF MEDICAL RESEARCH,2006,(01):117-122.
  • 8贾三庆;董晓冬;胡大一.曲美他嗪心肌细胞保护作用的临床研究[J]{H}中华心血管病杂志,2003201-208.
  • 9Barre J,Ledudal P,Oosterhuis B. Pharmacokinetic profile of a modified release formulation of trimetazidine(TMZ MR 35 mg)in the elderly and patients with renal failure[J].{H}Biopharmaceutics & Drug Disposition,2003,(04):159-164.
  • 10Yang Y,Mou Y,Hu SJ. Beneficial effect of rosuvastatin on cardiac dysfunction is associated with alterations in calcium-regulatory proteins[J].{H}European Journal of heart failure,2009,(01):6-13.

引证文献6

二级引证文献31

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部